Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Jason J. Luke(University of Chicago), Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Peter J. Hosein(Markey Cancer Center), Aurélien Marabelle(Institut Gustave Roussy), Robert I. Haddad(Georgetown University), Dejan Juric(Massachusetts General Hospital), Yuanxin Rong(Eisai (United States)), Andrés Cervantes(INCLIVA Health Research Institute), Yan Zhang(Qingdao University), Anupam M. Desai(Beth Israel Deaconess Medical Center), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Won Seog Kim(Samsung Medical Center), Patricia LoRusso(Yale Cancer Center)
Cited by 34
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k